{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:52:05Z","timestamp":1792021925994,"version":"4.4.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lilly Diabetes Alliance"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Studies that have reported lower risk for cardiovascular outcomes in users of Sodium\u2013Glucose Cotransporter-2 Inhibitors (SGLT-2i) are limited by residual cofounding and lack of information on prior cardiovascular disease (CVD). This study compared risk of cardiovascular events in patients within routine care settings in Europe and Asia with type 2 diabetes (T2D) initiating empagliflozin compared to dipeptidyl peptidase-4 inhibitors (DPP-4i) stratified by pre-existing CVD and history of heart failure (HF).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods and results<\/jats:title>\n                <jats:p>Adults initiating empagliflozin and DPP-4i in 2014\u20132018\/19 from 11 countries in Europe and Asia were compared using propensity score matching and Cox proportional hazards regression to assess differences in rates of primary outcomes: hospitalisation for heart failure (HHF), myocardial infarction (MI), stroke; and secondary outcomes: cardiovascular mortality (CVM), coronary revascularisation procedure, composite outcome including HHF or CVM, and 3-point major adverse cardiovascular events (MACE: MI, stroke and CVM). Country-specific results were meta-analysed and pooled hazard ratios (HR) with 95% confidence intervals (CI) from random-effects models are presented.<\/jats:p>\n                <jats:p>In total, 85,244 empagliflozin\/DPP4i PS-matched patient pairs were included with overall mean follow-up of 0.7\u00a0years. Among those with pre-existing CVD, lower risk was observed for HHF (HR 0.74; 95% CI 0.64\u20130.86), CVM (HR 0.55; 95% CI 0.38\u20130.80), HHF or CVM (HR 0.57; 95% CI 0.48\u20130.67) and stroke (HR 0.79; 95% CI 0.67\u20130.94) in patients initiating empagliflozin vs DPP-4i. Similar patterns were observed among patients without pre-existing CVD and those with and without pre-existing HF.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>These results from diverse patient populations in routine care settings across Europe and Asia demonstrate that initiation of empagliflozin compared to DPP-4i results in favourable cardioprotective effects regardless of pre-existing CVD or HF status.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-023-01963-9","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T08:18:24Z","timestamp":1693815504000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia"],"prefix":"10.1186","volume":"22","author":[{"given":"Dorte","family":"Vistisen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bendix","family":"Carstensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patorno","family":"Elisabetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Lanzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise Chia-Hui","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Yabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne H.-H.","family":"Sheu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheli","family":"Melzer-Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard W.","family":"Holl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00falio","family":"N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung Hwa","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrun","family":"Halvorsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisle","family":"Langslet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avraham","family":"Karasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Nystr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Niskanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Guleria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riho","family":"Klement","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Foersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Shay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisette","family":"Koeneman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Hoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soulmaz Fazeli","family":"Farsani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamlesh","family":"Khunti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Zaccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradhaa","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishnarajah","family":"Nirantharakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"EMPRISE EU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Brodovicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Zint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"F\u00f6rsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doron","family":"Rosenzweig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Lajer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkel","family":"Overgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie Toresson","family":"Grip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"S\u00f6reskog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Gunnarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Karlsdotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotta","family":"Stenman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikko","family":"Tuovinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neus","family":"Valveny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Casajust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Farmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Ternouth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Pernille","family":"Ofstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"East Asia Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaomi","family":"Nangaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Node","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Taneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsutaka","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Seino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingbo","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyu","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunwoo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,31]]},"reference":[{"issue":"7","key":"1963_CR1","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.jval.2017.12.019","volume":"21","author":"TR Einarson","year":"2018","unstructured":"Einarson TR, Acs A, Ludwig C, Panton UH. Economic burden of cardiovascular disease in type 2 diabetes: a systematic review. Value Health. 2018;21(7):881\u201390.","journal-title":"Value Health"},{"issue":"1","key":"1963_CR2","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12933-016-0451-0","volume":"15","author":"YM Kang","year":"2016","unstructured":"Kang YM, Kim YJ, Park JY, Lee WJ, Jung CH. Mortality and causes of death in a national sample of type 2 diabetic patients in Korea from 2002 to 2013. Cardiovasc Diabetol. 2016;15(1):131.","journal-title":"Cardiovasc Diabetol"},{"issue":"22","key":"1963_CR3","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"7","key":"1963_CR4","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"4","key":"1963_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"key":"1963_CR6","doi-asserted-by":"crossref","unstructured":"Darren K. McGuire, Weichung J. Shih, Francesco Cosentino, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis | Nephrology | JAMA Cardiology | JAMA Network. https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2771459. Accessed Apr 11 2022.","DOI":"10.1001\/jamacardio.2020.4511"},{"issue":"3","key":"1963_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"M Kosiborod","year":"2017","unstructured":"Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs. Circulation. 2017;136(3):249\u201359.","journal-title":"Circulation"},{"issue":"23","key":"1963_CR8","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1016\/j.jacc.2018.03.009","volume":"71","author":"M Kosiborod","year":"2018","unstructured":"Kosiborod M, Lam CSP, Kohsaka S, Kim DJ, Karasik A, Shaw J, et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study. J Am Coll Cardiol. 2018;71(23):2628\u201339.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"1963_CR9","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S2213-8587(20)30130-3","volume":"8","author":"S Kohsaka","year":"2020","unstructured":"Kohsaka S, Lam CSP, Kim DJ, Cavender MA, Norhammar A, J\u00f8rgensen ME, et al. Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study. Lancet Diabetes Endocrinol. 2020;8(7):606\u201315.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"1963_CR10","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S2213-8587(17)30258-9","volume":"5","author":"KI Birkeland","year":"2017","unstructured":"Birkeland KI, J\u00f8rgensen ME, Carstensen B, Persson F, Gulseth HL, Thuresson M, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol. 2017;5(9):709\u201317.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"1963_CR11","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/dom.13077","volume":"20","author":"F Persson","year":"2018","unstructured":"Persson F, Nystr\u00f6m T, J\u00f8rgensen ME, Carstensen B, Gulseth HL, Thuresson M, et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: a multinational observational study. Diabetes Obes Metab. 2018;20(2):344\u201351.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1963_CR12","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/dom.14593","volume":"24","author":"E Patorno","year":"2022","unstructured":"Patorno E, Pawar A, Wexler DJ, Glynn RJ, Bessette LG, Paik JM, et al. Effectiveness and safety of empagliflozin in routine care patients: results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study. Diabetes Obes Metab. 2022;24(3):442\u201354.","journal-title":"Diabetes Obes Metab"},{"issue":"370","key":"1963_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3342","volume":"2020","author":"KB Filion","year":"2020","unstructured":"Filion KB, Lix LM, Yu OH, Dell\u2019Aniello S, Douros A, Shah BR, et al. Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study. BMJ. 2020;2020(370): m3342.","journal-title":"BMJ"},{"key":"1963_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14261","author":"SJ Han","year":"2021","unstructured":"Han SJ, Ha KH, Lee N, Kim DJ. Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a nationwide population-based study. Diabetes Obes Metab. 2021. https:\/\/doi.org\/10.1111\/dom.14261.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"1963_CR15","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1007\/s11606-010-1609-1","volume":"26","author":"WH Shrank","year":"2011","unstructured":"Shrank WH, Patrick AR, Alan BM. Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. J Gen Intern Med. 2011;26(5):546\u201350.","journal-title":"J Gen Intern Med"},{"key":"1963_CR16","unstructured":"EUPAS27606. https:\/\/www.encepp.eu\/encepp\/viewResource.htm?id=45537. Accessed 16 Feb 2022."},{"issue":"8","key":"1963_CR17","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/pds.5071","volume":"29","author":"A Weisman","year":"2020","unstructured":"Weisman A, King LK, Mamdani M. Reporting and variability of constructing medication treatment episodes in pharmacoepidemiology studies: a methodologic systematic review using the case study of DPP-4 inhibitors and cardiovascular outcomes. Pharmacoepidemiol Drug Saf. 2020;29(8):939\u201350.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"1963_CR18","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1002\/pds.1674","volume":"17","author":"PC Austin","year":"2008","unstructured":"Austin PC. Assessing balance in measured baseline covariates when using many-to-one matching on the propensity-score. Pharmacoepidemiol Drug Saf. 2008;17(12):1218\u201325.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"1963_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.183","volume":"4","author":"Y Seino","year":"2021","unstructured":"Seino Y, Kim DJ, Yabe D, Tan ECH, Chung WJ, Ha KH, et al. Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: results from the EMPRISE East Asia study. Endocrinol Diabetes Metab. 2021;4(1): e00183.","journal-title":"Endocrinol Diabetes Metab"},{"issue":"327","key":"1963_CR20","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"1","author":"J Higgins","year":"2003","unstructured":"Higgins J, Thompson S, Deeks J, Altman D. Measuring inconsistency in meta-analyses. BMJ (Clin Res Ed). 2003;1(327):557\u201360.","journal-title":"BMJ (Clin Res Ed)"},{"key":"1963_CR21","unstructured":"R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http:\/\/www.R-project.org\/."},{"issue":"25","key":"1963_CR22","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1161\/CIRCULATIONAHA.118.039177","volume":"139","author":"E Patorno","year":"2019","unstructured":"Patorno E, Pawar A, Franklin JM, Najafzadeh M, D\u00e9ruaz-Luyet A, Brodovicz KG, et al. Empagliflozin and the risk of heart failure hospitalization in routine clinical care. Circulation. 2019;139(25):2822\u201330.","journal-title":"Circulation"},{"issue":"3","key":"1963_CR23","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.kint.2015.12.038","volume":"89","author":"H Rajasekeran","year":"2016","unstructured":"Rajasekeran H, Lytvyn Y, Cherney DZI. Sodium\u2013glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis. Kidney Int. 2016;89(3):524\u20136.","journal-title":"Kidney Int"},{"issue":"2","key":"1963_CR24","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","volume":"60","author":"V Vallon","year":"2017","unstructured":"Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017;60(2):215\u201325.","journal-title":"Diabetologia"},{"issue":"21","key":"1963_CR25","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","volume":"140","author":"S Verma","year":"2019","unstructured":"Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease. Circulation. 2019;140(21):1693\u2013702.","journal-title":"Circulation"},{"issue":"4","key":"1963_CR26","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.pcad.2019.07.005","volume":"62","author":"V Garg","year":"2019","unstructured":"Garg V, Verma S, Connelly K. Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes. Prog Cardiovasc Dis. 2019;62(4):349\u201357.","journal-title":"Prog Cardiovasc Dis"},{"issue":"4","key":"1963_CR27","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1002\/ehf2.13374","volume":"8","author":"S Verma","year":"2021","unstructured":"Verma S, Leiter LA, Zinman B, Sharma A, Mattheus M, Fitchett D, et al. Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG OUTCOME trial. ESC Heart Fail. 2021;8(4):2603\u20137.","journal-title":"ESC Heart Fail"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01963-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-023-01963-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01963-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T00:17:51Z","timestamp":1700353071000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-023-01963-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,31]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1963"],"URL":"https:\/\/doi.org\/10.1186\/s12933-023-01963-9","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,31]]},"assertion":[{"value":"17 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data were obtained electronically and recorded from longitudinal secondary data sources at the national and regional level, separately in each included country. IQVIA received exclusively aggregate-level results from each country, in which study individuals in the countries cannot be identified. IQVIA did not have access to the individual-level data at any time during the study. Thus, no ethical approval and informed consent were required for this multi-country study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DV has received research grants from Bayer A\/S, Sanofi, Novo Nordisk A\/S and Boehringer Ingelheim. She holds shares in Novo Nordisk A\/S. PE is investigator of a research grant to the Brigham and Women\u2019s Hospital from Boehringer Ingelheim. DY has received consulting\/lecture fees from Eli Lilly Japan K.K., Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co. Ltd., and Takeda Pharmaceutical Company Limited, and grants from Arkray Inc., Novo Nordisk Pharma Ltd., Nippon Boehringer Ingelheim, Ono Pharmaceutical Co. Ltd., Taisho Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, and Terumo Corporation. DJK has received grants support from Boehringer Ingelheim, AstraZeneca, Sanofi-Aventis Korea, Jeil Pharmaceutical Chong Kun Dang, speaker fees from Boehringer Ingelheim, Novo Nordisk, Boryung, Hanmi, Novartis, Donga ST, Celltrion, AstraZeneca and Dong Wha Pharmaceuticals. WHHS has been an advisor and\/or speaker for AstraZeneca, Bayer HealthCare, Boehringer Ingelheim Pharmaceuticals, Daiichi-Sankyo, Eli Lilly and Company, Merck Sharp & Dohme, Mitsubishi Tanabe Pharma Corporation, Novartis Pharmaceuticals, Novo Nordisk, Pfizer, Sanofi-Aventis, Takeda Pharmaceutical Company. RWH works at Ulm University, which received funds to conduct this study. RWH had no decision on the use of these funds, and he reports no additional conflict of interest. JN reports personal fees from AstraZeneca, Novartis, Boehringer Ingelheim, Eli Lilly, Rovi, Novo Nordisk, and Vifor Pharma (outside the submitted work). SH has received speaker fees from Sanofi, Novartis, Boehringer Ingelheim, Bayer, Pfizer and Bristol-Myers Squibb. GL has received consulting\/lecture fees from Sanofi and Boehringer Ingelheim. AK has received research grants and consulting fees from Boehringer Ingelheim; research grants from Astra Zeneca; research grants, consulting fees, and speaker fees from Novo Nordisk. TN has received unrestricted grants from AstraZeneca and NovoNordisk and has been a national advisor of Abbot, Amgen, Novo Nordisk, Sanofi-Aventis, Eli Lilly, MSD and Boehringer Ingelheim. LN has received speaker honoraria from Amgen, Boehringer Ingelheim, Novo Nordisk, Sanofi, MSD, Astra Zeneca; research support from Novo Nordisk to the hospital; and has participated in the scientific advisory boards of Amgen, Boehringer Ingelheim, Zeneca, MSD and Novo Nordisk. SG is an employee of IQVIA and contracted by Boehringer Ingelheim to interpret the results, write, review and revise the manuscript. RK and FH are employees of IQVIA contracted by Boehringer Ingelheim to conduct the analyses. MC, JF, CS and SFF are employees of Boehringer Ingelheim. LK is employee of Eli Lilly and Company and owns stock in Eli Lilly and Company. KK has acted as a consultant, speaker or received consultation\/lecture grants for investigator-initiated studies for Astra Zeneca, Novartis, Novo Nordisk, Sanofi-Aventis, Lilly and Merck Sharp & Dohme, Boehringer Ingelheim, Bayer. FZ has received speaker fees from Boehringer Ingelheim and Napp Pharmaceuticals. AS works at the University of Birmingham which received funds for the conduct of this study and had no decision on the use of these funds, and she reports no further conflict of interest. KN has been awarded research grants from the NIHR, the UKRI\/MRC, the Kennedy Trust for Rheumatology Research, Health Data Research UK, the Wellcome Trust, the European Regional Development Fund, the Institute for Global Innovation, Boehringer Ingelheim, Action Against Macular Degeneration Charity, Midlands Neuroscience Teaching and Development Funds, the South Asian Health Foundation, Vifor Pharma, the College of Police and CSL Behring (all payments were made to his academic institution); he also received consulting fees from Boehringer Ingelheim, Sanofi, Cegedim and MSD, and holds a leadership\/fiduciary role with NICST, a charity, and OpenClinical, a social enterprise. SL, ECHT, CMC, KHH, BC declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"233"}}